Vessel Wave Technologies

Coming – July 15

Meet One Of The Most Prolific Inventors In MedTech

Date and Time

July 15

–

4:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

Few people have shaped modern medical technology like Len Pinchuk, Ph.D. With 147 U.S. patents, more than 110 scientific publications, and over 10 companies founded, his inventions have been used in more than one billion patients worldwide. His innovations include the Nylon 12 angioplasty balloon, the helical wire stent, the modular aortic stent-graft, the TAXUS® drug-eluting coronary stent, PRESERFLO® MicroShunt, and numerous biomaterials and medical devices that have transformed patient care.

Now, Dr. Pinchuk is tackling another major challenge in cardiovascular medicine.

Join us for What’s Next In Med Tech, an exclusive webinar featuring Dr. Pinchuk and Allen Conger, CEO of Vessel Wave Technologies, as they discuss his latest innovation: a compliant aortic stent-graft designed to replicate the natural elasticity of the aorta. Unlike today’s rigid stent-grafts, which can alter normal cardiovascular function, Vessel Wave’s investigational technology is designed to more closely mimic the healthy aorta, with the goal of reducing long-term stress on the heart and improving patient outcomes.

During this discussion, Dr. Pinchuk will share:

  • The lessons learned from decades of medical device innovation.
  • Why current aortic stent-grafts may be creating unintended long-term complications.
  • The science behind Vessel Wave’s compliant stent-graft technology.
  • His perspective on where cardiovascular technology is headed next.

Whether you are interested in breakthrough medical technologies, the process of innovation, or hearing directly from one of the most accomplished inventors in modern medicine, this is a conversation you won’t want to miss.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.